Related Experiment Video
Updated: May 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran, electrical cardioversion and measuring the aPTT. A safety measure or an unnecessary assessment?
1Department of Cardiology, Ipswich Hospital, Suffolk, Ipswich, UK. avi.rahmat@yahoo.co.uk
Insights
Two patients on dabigatran for stroke prevention required electrical cardioversion. Measuring activated partial thromboplastin time (aPTT) before cardioversion revealed varying anticoagulant levels, complicating the procedure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Non-valvular atrial fibrillation (NVAF) necessitates anticoagulation for stroke prevention.
- Dabigatran is an oral anticoagulant used for stroke risk reduction in NVAF.
- Direct current electrical cardioversion (DCCV) is a procedure to restore normal heart rhythm.
Observation:
- Two cases of NVAF patients on dabigatran therapy were scheduled for DCCV.
- Activated partial thromboplastin time (aPTT) was measured pre-DCCV to assess dabigatran's anticoagulant effect.
- aPTT measurements yielded different results, impacting procedural planning.
Findings:
- The utility of aPTT for monitoring dabigatran's anticoagulant activity prior to DCCV can be variable.
- aPTT results influenced the management decisions in these otherwise routine cases.
- Standardized monitoring protocols for direct oral anticoagulants like dabigatran during cardioversion may be needed.
Implications:
- These cases highlight potential challenges in managing patients on dabigatran undergoing DCCV.
- Further research is warranted to establish optimal protocols for anticoagulant monitoring during cardioversion.
- Clinicians should be aware of the potential variability in aPTT measurements when assessing dabigatran's effect.
Abstract:
We present two case reports of patients treated with dabigatran for stroke prevention. Both have non-valvular atrial fibrillation and both were scheduled for direct current electrical cardioversion (DCCV). Both had their activated partial thromboplastin time (aPTT) measured prior to their DCCV to assess the anticoagulant activity of dabigatran. The decision to measure the aPTT resulted in differing levels to otherwise straightforward cases.
Related Concept Videos
Dysrhythmias V: Evaluating Dysrhythmias
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Dysrhythmias VI: Management of Dysrhythmias

